

FEB 27 2001


61016444

AMENDMENT TRANSMISSION LETTER		DOCKET NUMBER: P-IX 2947	
SERIAL NO: 09/203,768	FILING DATE: December 2, 1998	EXAMINER: L. Helms	GROUP ART UNIT: 1642
INVENTION: TUMOR SPECIFIC HUMAN MONOCLOINAL ANTIBODIES AND METHODS OF USE			

TO COMMISSIONER FOR PATENTS

RECEIVED

I hereby certify that this correspondence
is being deposited with the United States
Postal Service as first class mail in an
envelope addressed to: Commissioner for
Patents, Washington, D.C., POST OFFICE CENTER 1600/2900
February 20, 2001.

By: 
David A. Gay, Reg. No. 39,200

February 20, 2001
Date of Signature

03/01/2001 NSBREN1 0000024 09203768

18.00 OP
445.00 TD

Transmitted herewith is a response to Office Action mailed
August 18, 2000, in the above-identified application.

- Small Entity status of this application has been established under 37 CFR 1.27 by a verified statement previously submitted.
- Petition for Extension of Time is enclosed (in duplicate).
- Exhibits A, B, C and D.
- An additional claims fee is required and has been calculated as shown below:

CLAIMS AS AMENDED

	NUMBER AFTER AMEND- MENT	HIGHEST NUMBER PREVIOUSLY PAID FOR	NUMBER OF EXTRA CLAIMS PRESENTED	RATE		FEE	
				SMALL ENTITY	OTHER ENTITY	SMALL ENTITY	OTHER ENTITY
TOTAL CLAIMS	48-20	-	46	-	2	x \$9	\$18
INDEPENDENT CLAIMS	14-3	-	14	-	0	x \$40	\$80
FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM		YES	NO			\$135	\$270
						TOTAL ADDITIONAL FEE	\$18

* If the "HIGHEST NUMBER PREVIOUSLY PAID FOR" is less than 20, write "20" in this space.

** If the "HIGHEST NUMBER PREVIOUSLY PAID FOR" is less than 3, write "3" in this space.

*** If the difference between the "NUMBER AFTER AMENDMENT" and the "HIGHEST NUMBER PREVIOUSLY PAID FOR" is less than 0, write "0" in the space.

Please charge my Deposit Account No. 03-0370 the amount of
\$. A duplicate copy of this sheet is enclosed.

Inventors: Watkins and Huse
Serial No.: 09/203,768
Filed: December 2, 1998
Page 2

A check in the amount of \$463.00 is enclosed, \$18.00 of which covers the additional claims fee and \$445.00 of which covers the fee for a three-month extension of time.

The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 03-0370. A duplicate copy of this sheet is enclosed.

Any additional filing fees required under 37 C.F.R. 1.16.

Any patent application processing fees under 37 C.F.R. 1.17.

The Commissioner is hereby authorized to charge to Deposit Account No. 03-0370 any fees under 37 CFR 1.17 which may be required under 37 CFR 1.136(a)(3) for an extension of time in any concurrent or future reply requiring a petition for extension of time. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

February 20, 2001
Date



David A. Gay
Registration No. 39,200
CAMPBELL & FLORES LLP
4370 La Jolla Village Drive
7th Floor
San Diego, California 92122
858-535-9001
USPTO CUSTOMER NO. 23601



14/3/01
Amalfi/B
PATENT
Our Docket: P-IX 2947


RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

MAR 03 2001

In re Application of)
Watkins and Huse)
Serial No: 09/203,768)
Filed: December 2, 1998)
For: TUMOR SPECIFIC HUMAN)
MONOCLONAL ANTIBODIES)
AND METHODS OF USE)

I hereby certify that this correspondence
is being deposited with the United States
Postal Service as first class mail in an
envelope addressed to: Commissioner for
Patents, Washington, D.C., 20231 on
February 20, 2001.

By: 
David A. Gay, Reg. No. 39,200

February 20, 2001
Date of Signature

Commissioner for Patents
Washington, D.C. 20231

TECH CENTER 1600/2900

RESPONSE TO OFFICE ACTION

Responsive to the Office Action mailed August 18, 2000,
consideration of the following Remarks is respectfully requested.

AMENDMENTS

In the claims:

Please amend the claims as follows:

B1
1. (Amended) A human monoclonal antibody or
functional fragment thereof, comprising at least one
Complementarity Determining Region (CDR) having substantially the
amino acid sequence of a CDR of SEQ ID NO:2 or SEQ ID NO:4,
wherein said antibody or functional fragment thereof binds a
neoplastic cell or antigen thereof.
C1